We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No approval data available
- The phase 2 LenCabo trial showed lenvatinib plus everolimus led to significantly greater reductions in BMI, skeletal muscle mass index, and subcutaneous adiposity at 4 months versus cabozantinib in metastatic ccRCC. - Dr. María Teresa Bourlon emphasized that this catabolic signal raises concerns for older, frail, or weight-compromised patients, potentially impacting quality of life and dose delivery. - Quality-of-life comparison at day 60 was inconclusive due to only 38 of 86 patients completing both assessments, limiting interpretability. - Clinicians are urged to carefully evaluate baseline patient fitness and body composition when considering lenvatinib/everolimus in this setting.
